Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
NOD9 Double Nickase Plasmid (h): sc-402937-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- NOD9 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- NOD9 Double Nickase Plasmid (h) and NOD9 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting NLRX1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: NOD9 Antibody (F-2): sc-374514
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NOD9 Double Nickase Plasmid (h) | sc-402937-NIC | 20 µg | $410.00 |
NLRX1 (also known as NOD9) is a mitochondrial NOD-like receptor that modulates innate immune signaling and cellular stress responses. By interacting with MAVS and related adaptors, NLRX1 can tune RIG-I–like receptor pathways, NF-κB activity, and type I interferon outputs, while also influencing reactive oxygen species generation and mitochondrial homeostasis. It has been implicated in regulation of autophagy and inflammatory signaling programs that shape host–pathogen interactions and tissue-specific immune balance. Dysregulated NLRX1 activity is frequently studied in the context of chronic inflammation, infectious disease biology, and immune-associated mechanisms relevant to cancer and metabolic disorders.
NOD9 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the NLRX1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within NLRX1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt NLRX1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of NLRX1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.